CAP37 Peptide Compounds for Gram-Negative Bacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gram-negative bacterial infections lack effective novel antibiotics, with limited options available due to antibiotic resistance, and existing peptides like CAP37(20-44) face challenges in scalability, purity, and maintaining antibacterial activity.
Innovation Solution
Development of novel peptide compounds derived from CAP37, such as BCC02-5RMP, BCC03-5RMP, and BCC04-5RMP, which incorporate additional arginine residues and solubilizing moieties like AEEA, enhancing solubility, purity, and antibacterial efficacy against Gram-negative bacteria like Pseudomonas aeruginosa and Escherichia coli.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the native CAP37(20-44) peptide sequence is used, then antibacterial activity is achieved, but scalability and purity for commercialization cannot be met
Solution Approach 1:
The patent modifies the native CAP37(20-44) peptide sequence by substituting specific amino acid residues (e.g., replacing hydrophobic residues with polar or charged residues, or vice versa) to alter the peptide's physicochemical properties. These parameter changes improve solubility and manufacturability while preserving or enhancing antibacterial activity against Gram-negative bacteria.
Solution Approach 2:
The patent creates hybrid peptide structures by combining the active antibacterial domain of CAP37 with additional functional domains or modifications (such as N-terminal or C-terminal extensions, or fusion with solubility-enhancing sequences). This composite approach maintains the core antibacterial function while adding properties that facilitate规模化 production and purification.
2Reliability
If peptide concentration is increased to enhance antibacterial efficacy, then bactericidal activity improves, but solubility limitations are reached
Solution Approach 1:
The patent systematically modifies amino acid residues to change the peptide's solubility parameters. This includes introducing charged residues (lysine, arginine, glutamate, aspartate) to enhance water solubility, or modifying hydrophobic interactions to prevent aggregation at higher concentrations. These changes enable the peptide to achieve therapeutic concentrations in solution without precipitation.
Solution Approach 2:
The patent may employ solubility-enhancing moieties or fusion partners (such as polyethylene glycol sequences, albumin-binding domains, or other solubility tags) that act as intermediaries to improve the peptide's interaction with water molecules and prevent aggregation, thereby enabling higher soluble concentrations.
3Ease of manufacture
If peptide modifications are made to improve solubility, then manufacturability increases, but antibacterial activity may be compromised
Solution Approach 1:
The patent applies modifications selectively at specific locations within the peptide sequence (such as N-terminal or C-terminal regions, or surface-exposed residues) rather than throughout the entire structure. This localized approach allows solubility improvements without disrupting the critical antibacterial domain's three-dimensional structure and function.
Solution Approach 2:
The patent divides the peptide into functional domains: a core antibacterial domain that maintains bactericidal activity and peripheral or surface residues that are modified to improve solubility. This segmentation allows independent optimization of each function - the core domain preserves antibacterial activity while the modified regions enhance manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate significant bactericidal activity, achieving a 5-log reduction in bacterial load with improved solubility and purity, effectively killing resistant strains and neutralizing lipopolysaccharide toxicity, while minimizing cytotoxicity to mammalian cells.
Implementation Method 1
bind and neutralize the toxic effects of endotoxin (a.k.a., lipopolysaccharide, or LPS)
Implementation Method 2
demonstrated to have strong bactericidal activity against Gram negative bacteria including Salmonella typhimurium, Escherichia coli, and Pseudomonas aeruginosa
Data Source
Figure 1~2
Figure 3~5
Figure 4A~4D
AI summary
Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides. Effective treatment of Gram negative bacterial infections has suffered due to a dearth of new antibiotics in the pharmaceutical pipeline.